Filtered By:
Therapy: Gene Therapy

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 5568 results found since Jan 2013.

Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma.
In conclusion, the combination of siRNA-mediated gene-silencing strategy can be considered as a valuable and safe approach for sensitizing cancer cells to chemotherapeutic agents thus proposed further studies regarding this issue to approve some siRNA based therapeutics for using in clinic. PMID: 31348981 [PubMed - as supplied by publisher]
Source: Gene - July 22, 2019 Category: Genetics & Stem Cells Authors: Saatloo MV, Aghbali AA, Koohsoltani M, Khosroushahi AY Tags: Gene Source Type: research

Combination of photodynamic therapy and gene silencing achieved through the hierarchical self-assembly of porphyrin-siRNA complexes
Publication date: Available online 31 July 2019Source: International Journal of PharmaceuticsAuthor(s): Nabila Laroui, Maëva Coste, Laure Lichon, Yannick Bessin, Magali Gary-Bobo, Geneviève Pratviel, Colin Bonduelle, Nadir Bettache, Sébastien UlrichAbstractIn this work, we implemented a supramolecular approach in order to combine photodynamic therapy (PDT) with gene therapy. We made use of a simple cationic guanidylated porphyrin (H2‑PG) with the hypothesis that porphyrin aggregates should be capable of complexing siRNA through multivalent interactions and thus contribute to its intracellular delivery, while remaining...
Source: International Journal of Pharmaceutics - August 1, 2019 Category: Drugs & Pharmacology Source Type: research

Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy
Conclusion: Si/PNPs@HeLa, by integrating immune escape and tumor-homing ability, can serve as an efficient dual-drug delivery system to achieve precise treatment of cervical cancer through chemo-gene combined therapy.
Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Cong Xu, Wan Liu, Yuan Hu, Weiping Li, Wen Di Tags: Research Paper Source Type: research

A Nanoparticle-Conjugated Anti-TBK1 siRNA Induces Autophagy-Related Apoptosis and Enhances cGAS-STING Pathway in GBM Cells
CONCLUSION: The rGO-PEG could be an efficient system facilitating the delivery of specific siRNA. TBK1si/rGO-PEG could be a novel strategy for the treatment of GBM.PMID:34931127 | PMC:PMC8684524 | DOI:10.1155/2021/6521953
Source: Evidence-based Complementary and Alternative Medicine - December 21, 2021 Category: Complementary Medicine Authors: Shengchao Xu Xi Yan Lu Tang Gan Dai Chengke Luo Source Type: research

Peptidyl Virus-Like Nanovesicles as Reconfigurable "Trojan Horse" for Targeted siRNA Delivery and Synergistic Inhibition of Cancer Cells
Small. 2022 Nov 13:e2204959. doi: 10.1002/smll.202204959. Online ahead of print.ABSTRACTThe self-assembly of peptidyl virus-like nanovesicles (pVLNs) composed of highly ordered peptide bilayer membranes that encapsulate the small interfering RNA (siRNA) is reported. The targeting and enzyme-responsive sequences on the bilayer's surface allow the pVLNs to enter cancer cells with high efficiency and control the release of genetic drugs in response to the subcellular environment. By transforming its structure in response to the highly expressed enzyme matrix metalloproteinase 7 (MMP-7) in cancer cells, it helps the siRNA esca...
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Zixuan Wang Dongzhao Hao Yuefei Wang Jinwu Zhao Jiaxing Zhang Xi Rong Jiaojiao Zhang Jiwei Min Wei Qi Rongxin Su Mingxia He Source Type: research

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
ConclusionThe results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.
Source: Journal of Cancer Research and Clinical Oncology - July 1, 2023 Category: Cancer & Oncology Source Type: research

A review of the current status of siRNA nanomedicines in the treatment of cancer.
Abstract RNA interference currently offers new opportunities for gene therapy by the specific extinction of targeted gene(s) in cancer diseases. However, the main challenge for nucleic acid delivery still remains its efficacy through intravenous administration. Over the last decade, many delivery systems have been developed and optimized to encapsulate siRNA and to specifically promote their delivery into tumor cells and improve their pharmacokinetics for anti-cancer purposes. This review aims to sum up the potential targets in numerous pathways and the properties of recently optimized siRNA synthetic nanomedicine...
Source: Biomaterials - May 30, 2013 Category: Materials Science Authors: Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C Tags: Biomaterials Source Type: research

Application of Target Peptide in siRNA Delivery 
for the Research of Lung Cancer Therapy
This article will make a brief overview of target peptides applying in siRNA dilivery for the research of lung cancer treatment. DOI: 10.3779/j.issn.1009-3419.2014.09.06
Source: Chinese Journal of Lung Cancer - September 19, 2014 Category: Cancer & Oncology Source Type: research

Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action
Publication date: 15 May 2015 Source:International Journal of Pharmaceutics, Volume 485, Issues 1–2 Author(s): Volha Dzmitruk , Aleksandra Szulc , Dzmitry Shcharbin , Anna Janaszewska , Natallia Shcharbina , Joanna Lazniewska , Darya Novopashina , Marina Buyanova , Maksim Ionov , Barbara Klajnert-Maculewicz , Rafael Gómez-Ramirez , Serge Mignani , Jean-Pierre Majoral , Maria Angeles Muñoz-Fernández , Maria Bryszewska This paper examines a perspective to use newly engineered nanomaterials as effective and safe carriers for gene therapy of cancer. Three different groups of cationic dendrimers (PAMAM, phosphorus, and c...
Source: International Journal of Pharmaceutics - March 27, 2015 Category: Drugs & Pharmacology Source Type: research

Gold nanorod delivery of LSD1 siRNA induces human mesenchymal stem cell differentiation.
In this study, we have developed poly-sodium 4-styrenesulfonate (PSS) and poly-allylamine hydrochloride (PAH) coated AuNR-based nanocarriers, which are capable of delivering small interfering RNA (siRNA) against LSD1 to induce the differentiation of human mesenchymal stem cells. To further study the mechanism, we tested the stemness and differentiation genes and found that they have been changed with LSD1 down-regulation. In addition, with the hepatocyte growth factor (HGF), LSD1 siRNA delivery by AuNRs could promote the differentiation of the human mesenchymal stem cells (human MSCs) into a hepatocyte lineage in vitro. Ou...
Source: Appl Human Sci - June 7, 2015 Category: Physiology Authors: Zhao X, Huang Q, Jin Y Tags: Mater Sci Eng C Mater Biol Appl Source Type: research

Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.
Abstract Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Loss of imprinting (LOI) of the insulin-like growth factor 2 (IGF2) gene is an epigenetic abnormality phenomenon in CRC. Recently observed association of CRC with cluster of differentiation 147 (CD147) could provide a novel approach for gene therapy. In the present study, we investigated the feasibility of using adenovirus‑mediated siRNA targeting CD147 based on the IGF2 LOI system for targeted gene therapy of CRC. A novel adenovirus-mediated siRNA targeting CD147, rAd-H19-CD147mirsh, which was driven by the IGF2 imprintin...
Source: International Journal of Oncology - September 23, 2015 Category: Cancer & Oncology Authors: Pan Y, He B, Chen J, Sun H, Deng Q, Wang F, Ying H, Liu X, Lin K, Peng H, Xie H, Wang S Tags: Int J Oncol Source Type: research

siRNA Delivery by Stimuli-Sensitive Nanocarriers.
Abstract Since its discovery in the late 1990, small interfering RNA (siRNA) have quickly crept into the biopharmaceutical research as a new and powerful tool for the treatment of different human diseases based on altered gene-expression. Despite promising data from many pre-clinical studies, concrete hurdles still need to be overcome to bring therapeutic siRNAs in clinic. The design of stimuli-sensitive nanopreparations for gene therapy is a lively area of the current research. Compared to conventional systems for siRNA delivery, this type of platform can respond to local stimuli that are characteristics of the p...
Source: Current Pharmaceutical Design - October 23, 2015 Category: Drugs & Pharmacology Authors: Salzano G, Costa DF, Torchilin VP Tags: Curr Pharm Des Source Type: research

Correction of mutant p63 in EEC syndrome using siRNA mediated allele specific silencing restores defective stem cell function
This study demonstrates the phenotypic correction of mutant stem cells (OMESCs) in EEC syndrome by means of siRNA mediated allele‐specific silencing with restoration of function. The application of siRNA, alone or in combination with cell‐based therapies, offers a therapeutic strategy for corneal blindness in EEC syndrome. This article is protected by copyright. All rights reserved.
Source: Stem Cells - February 17, 2016 Category: Stem Cells Authors: Vanessa Barbaro, Annamaria A. Nasti, Claudia Del Vecchio, Stefano Ferrari, Angelo Migliorati, Paolo Raffa, Vincenzo Lariccia, Patrizia Nespeca, Mariangela Biasolo, Colin E. Willoughby, Diego Ponzin, Giorgio Palù, Cristina Parolin, Enzo Di Iorio Tags: Regenerative Medicine Source Type: research

Correction of Mutant p63 in EEC Syndrome Using siRNA Mediated Allele‐Specific Silencing Restores Defective Stem Cell Function
This study demonstrates the phenotypic correction of mutant stem cells (OMESCs) in EEC syndrome by means of siRNA mediated AS silencing with restoration of function. The application of siRNA, alone or in combination with cell‐based therapies, offers a therapeutic strategy for corneal blindness in EEC syndrome. Stem Cells 2016; 00:000—000
Source: Stem Cells - March 16, 2016 Category: Stem Cells Authors: Vanessa Barbaro, Annamaria A. Nasti, Claudia Vecchio, Stefano Ferrari, Angelo Migliorati, Paolo Raffa, Vincenzo Lariccia, Patrizia Nespeca, Mariangela Biasolo, Colin E. Willoughby, Diego Ponzin, Giorgio Palù, Cristina Parolin, Enzo Iorio Tags: Regenerative Medicine Source Type: research